Literature DB >> 26563159

FAS Haploinsufficiency Caused by Extracellular Missense Mutations Underlying Autoimmune Lymphoproliferative Syndrome.

María Gabriela Simesen de Bielke1, Laura Perez2, Judith Yancoski3, João Bosco Oliveira4, Silvia Danielian3.   

Abstract

Mutations in the FAS gene are the most common cause of Autoimmune Lymphoproliferative Syndrome (ALPS), and the majority of them affect the intracellular domain of FAS protein, particularly the region termed death domain. However, approximately one third of these mutations affect the extracellular region of FAS and most are stop codons, with very few missense changes having been described to date. We previously described 7 patients with a FAS missense extracellular mutation, C107Y, two in homozygozity and 5 in heterozygosity. We investigated here the mechanistic effects of this mutation and observed that the homozygous patients did not show any FAS surface expression, while the heterozygous patients had diminished receptor expression. Aiming to understand why a missense mutation was abolishing receptor expression, we analyzed intracellular FAS protein trafficking using fluorescent fusion proteins of wild type FAS, two missense extracellular mutants (FAS-C107Y and FAS-C104Y) and one missense change localized in the intracellular region, FAS-D260E. The FAS-C107Y and FAS-C104Y mutants failed to reach the cell surface, being retained at the endoplasmic reticulum, unlike the WT or the FAS-D260E which were clearly expressed at the plasma membrane. These results support haploinsufficiency as the underlying mechanism involved in the pathogenesis of ALPS caused by extracellular FAS missense mutations.

Entities:  

Keywords:  ALPS; FAS; apoptosis; haploinsufficiency

Mesh:

Substances:

Year:  2015        PMID: 26563159     DOI: 10.1007/s10875-015-0210-0

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  29 in total

1.  Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations.

Authors:  R M Siegel; J K Frederiksen; D A Zacharias; F K Chan; M Johnson; D Lynch; R Y Tsien; M J Lenardo
Journal:  Science       Date:  2000-06-30       Impact factor: 47.728

2.  Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop.

Authors:  Joao B Oliveira; Jack J Bleesing; Umberto Dianzani; Thomas A Fleisher; Elaine S Jaffe; Michael J Lenardo; Frederic Rieux-Laucat; Richard M Siegel; Helen C Su; David T Teachey; V Koneti Rao
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

3.  Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation.

Authors:  Aude Magerus-Chatinet; Bénédicte Neven; Marie-Claude Stolzenberg; Cécile Daussy; Peter D Arkwright; Nina Lanzarotti; Catherine Schaffner; Sophie Cluet-Dennetiere; Filomeen Haerynck; Gérard Michel; Christine Bole-Feysot; Mohammed Zarhrate; Isabelle Radford-Weiss; Serge P Romana; Capucine Picard; Alain Fischer; Frédéric Rieux-Laucat
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 4.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

5.  Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.

Authors:  G H Fisher; F J Rosenberg; S E Straus; J K Dale; L A Middleton; A Y Lin; W Strober; M J Lenardo; J M Puck
Journal:  Cell       Date:  1995-06-16       Impact factor: 41.582

6.  Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.

Authors:  A Oehm; I Behrmann; W Falk; M Pawlita; G Maier; C Klas; M Li-Weber; S Richards; J Dhein; B C Trauth
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

7.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.

Authors:  S T Ju; D J Panka; H Cui; R Ettinger; M el-Khatib; D H Sherr; B Z Stanger; A Marshak-Rothstein
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

Review 8.  Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways.

Authors:  F Rieux-Laucat; F Le Deist; A Fischer
Journal:  Cell Death Differ       Date:  2003-01       Impact factor: 15.828

9.  Different molecular behavior of CD40 mutants causing hyper-IgM syndrome.

Authors:  Gaetana Lanzi; Simona Ferrari; Mauno Vihinen; Stefano Caraffi; Necil Kutukculer; Luisa Schiaffonati; Alessandro Plebani; Luigi Daniele Notarangelo; Anna Maria Fra; Silvia Giliani
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

10.  Identification of amino acid residues important for ligand binding to Fas.

Authors:  G C Starling; J Bajorath; J Emswiler; J A Ledbetter; A Aruffo; P A Kiener
Journal:  J Exp Med       Date:  1997-04-21       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.